Add Formweb to your mobile device
Approved Formulary
Search results for:
nevirapine
nevirapine
Brand names: Viramune
| Form | Strength |
|---|---|
| TABLET, ORAL | 200 mg |
Display HIV Nonnucleoside Reverse Transcriptase Inhibitors Class:
08180816
Medication comments:
| Per policy, these hazardous drugs have special waste requirements. | |
|---|---|
| Generic (Brand) | Waste Requirements |
| nevirapine (Viramune) | Hazardous Waste ⇒ BLACK BUCKET |
| USP <800> Hazardous Drugs | ||||||
|---|---|---|---|---|---|---|
| Per Policy, these drugs have special handling requirements (any drug with an "AOR" is exempt from these requirements under normal circumstances). | ||||||
| generic (Brand) Route | Relative Risk Level | AOR? | NIOSH 2024 Table | MSHI?↑ | Warnings | |
| nevirapine (Viramune) PO | Medium | N/A | 2↑ | |||
| NIOSH Supplemental information (2016): in laboratory studies, hepatocellular adenomas and carcinomas at doses lower than human dose FDA Pregancy Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women; | ||||||
Last updated: May. 28, 2025
- Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug
- Hazardous Waste BLACK BUCKET
- Black Box Warnings Hepatotoxicity; dermal reactions; patient monitoring